CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

Application Number: 020764 and 020241/S002

Trade Name: LAMICTAL CHEWABLE DISPERSIBLE TABLETS

Generic Name: LAMOTRIGINE

Sponsor: GLAXO WELLCOME, INC

Approval Date: 08/24/98

Indication(s): ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS.
## CONTENTS

<table>
<thead>
<tr>
<th>Item</th>
<th>Included</th>
<th>Pending Completion</th>
<th>Not Prepared</th>
<th>Not Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tentative Approval Letter</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Approvable Letter</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Final Printed Labeling</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA/FONSI</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopharmaceutics Review(s)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioequivalence Review(s)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administrative Document(s)/Correspondence</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
NDA 20-764
NDA 20-241/5-002

Glaxo Wellcome, Inc.
Attention: Elizabeth A. McConnell, Pharm D.
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709

Dear Dr. McConnell:

Please refer to your new drug application (NDA) dated September 16, 1996, received September 17, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lamictal (lamotrigine) Chewable Dispersible Tablets, 5mg, 25mg, and 100mg.

We also refer to your supplemental new drug application dated September 16, 1996, received September 17, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lamictal (lamotrigine) 25mg, 100mg, 150mg, and 200mg.

We acknowledge receipt of your additional correspondence and amendments to the NDA dated:

<table>
<thead>
<tr>
<th>Date</th>
<th>Correspondence Date</th>
<th>Acknowledged Date</th>
</tr>
</thead>
</table>

We also acknowledge receipt of your additional correspondence and amendments to the supplemental NDA dated:

<table>
<thead>
<tr>
<th>Date</th>
<th>Correspondence Date</th>
<th>Acknowledged Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 5, 1997</td>
<td>July 29, 1998</td>
<td>August 14, 1998</td>
</tr>
<tr>
<td>June 24, 1998</td>
<td>August 6, 1998</td>
<td>August 19, 1998 (2)</td>
</tr>
</tbody>
</table>

Your submissions of February 23, 1998 constitute full responses to our December 3, 1997 action letter for these applications. The user fee goal date for these applications is August 24, 1998.

The Lamictal Chewable Dispersible Tablet application provides bioequivalency data to support a new dosage form of lamotrigine, and clinical data to support a new indication for the use of lamotrigine, as compared to the already approved Lamictal Tablet. Specifically, the new indication is for the use of lamotrigine for adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients.

The Lamictal Tablet supplemental application incorporates by reference the clinical data contained in the Lamictal CD Chewable Tablet application so that the approved compressed tablet formulation can gain the new indication, as well. This cross-reference also allows for the development of one label for both lamotrigine products.

BEST POSSIBLE COPY
We have completed the review of these applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the submitted labeling (package insert dated August 20, 1998, patient package insert dated August 20, 1998, immediate container and carton labels dated June 8, 1998) with the revisions listed below. Accordingly, these applications are approved effective on the date of this letter.

1. The chemical name in the DESCRIPTION section has been changed from "6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine" to "3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine".

2. The following paragraph has been added, as the second paragraph, to the General Dosing Considerations subsection of the DOSAGE AND ADMINISTRATION section:

   "This section provides specific dosing recommendations for patients 2 to 12 years of age and patients greater than 12 years of age. Within each of these age groups, specific dosing recommendations are provided depending upon whether or not the patient is receiving VPA (Tables 7 and 8 for patients 2 to 12 years of age, Tables 9 and 10 for patients greater than 12 years of age). In addition, the section provides a discussion of dosing for those patients receiving concomitant AEDs that have not been systematically evaluated in combination with LAMICTAL."

3. The usual maintenance dose portion of Table 7 has been revised to the following:

   Usual maintenance dose: 1 to 5 mg/kg/day (maximum 200 mg/day in one or two divided doses). To achieve the usual maintenance dose, subsequent doses should be increased every 1 to 2 weeks as follows: Calculate 0.3 mg/kg/day, round this amount down to the nearest 5 mg, and add this amount to the previously administered daily dose.

4. The usual maintenance dose portion of Table 8 has been revised to the following:

   Usual maintenance dose: 5 to 15 mg/kg/day (maximum 400 mg/day in two divided doses). To achieve the usual maintenance dose, subsequent doses should be increased every 1 to 2 weeks as follows: Calculate 1.2 mg/kg/day, round this amount down to the nearest 5 mg, and add this amount to the previously administered daily dose every 1 to 2 weeks.

We note that you have agreed to these revisions as per your August 21, 1998 submission.

These revisions are terms of the NDA and supplemental NDA approval. Marketing these products before making the revisions, exactly as requested, in the products' final printed labeling (FPL) may render the products misbranded and an unapproved new drug.

BEST POSSIBLE COPY
Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FINAL PRINTED LABELING" for approved NDA 20-764 and NDA 20-241/5-002. Approval of this submission by FDA is not required before the labeling is used.

Should additional information relating to the safety and effectiveness of the drug become available, revision of labeling may be required.

Phase 4 Commitments

We remind you of your Phase 4 commitments specified in your submission dated August 19, 1998. These commitments, along with any completion dates agreed upon, are listed below.

Protocols, data, and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. If an IND is not required to meet your Phase 4 commitments, please submit protocols, data and final reports to this NDA as correspondence. In addition, under 21 CFR 314.82(b)(2)(vi), we request that you include a status summary of each commitment in your annual report to this NDA. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments."

Pediatric Exclusivity

We note that your March 11, 1998 submission requests "a determination ... that marketing submissions and approvals for any product containing lamotrigine be subject to the market-exclusivity extension provisions of new section 505A of the Federal Food, Drug, and Cosmetic Act," and specifically refers to two pediatric indications. Lennox-Gastaut syndrome
We have been advised by the
CDER Pediatric Exclusivity Implementation Team that the Lennox-Gastaut syndrome data is not
eligible for pediatric exclusivity because study reports for the Lennox-Gastaut indication were
submitted prior to November 21, 1997.

Other

Validation of the regulatory methods has not been completed. At the present time, it is the policy
of the Center not to withhold approval because the methods are being validated. Nevertheless,
we expect your continued cooperation to resolve any problems that may be identified.

Please submit one market package of the drug product (containers and carton only) when it is
available.

We remind you that you must comply with the requirements for an approved NDA set forth
under 21 CFR 314.80 and 314.81.

If you have any questions, contact Jacqueline H. Ware, Pharm.D., Regulatory Management
Officer, at (301) 594-2850.

Sincerely,

Paul Leber, M.D.
Director
Division of Neuropharmaceutical Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

BEST POSSIBLE COPY
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 020764 and 020241/S002

APPROVABLE LETTER
Dear Dr. McConnell:

Please refer to your new drug application dated September 16, 1996, received September 17, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lamictal CD (lamotrigine) Chewable Dispersible Tablets, 5mg, 25mg, and 100mg.

We also refer to your supplemental new drug application dated September 16, 1996, received September 17, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lamictal (lamotrigine) 25mg, 100mg, 150mg, and 200mg.

We acknowledge receipt of your additional correspondence and amendments to the NDA dated:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>December 4, 1996</td>
<td>April 9, 1997</td>
<td>July 1, 1997</td>
<td>September 29, 1997</td>
</tr>
<tr>
<td>March 12, 1997 (2)</td>
<td>June 3, 1997</td>
<td>August 8, 1997</td>
<td></td>
</tr>
</tbody>
</table>

We also acknowledge receipt of your additional correspondence and amendments to the supplemental NDA dated July 25, 1997, July 29, 1997, August 8, 1997, and August 28, 1997.

The original User Fee goal date for these applications was September 17, 1997. Your submissions of July 22, 1997 (for the NDA) and July 25, 1997 (for the supplemental NDA) extended the User Fee goal date to December 17, 1997.

The Lamictal CD Chewable Dispersible Tablet application provides bioequivalency data to support a new dosage form of lamotrigine, and clinical data to support a new indication for the use of lamotrigine, as compared to the already approved Lamictal Tablet. Specifically, the new indication is for the use of lamotrigine for adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients.
The Lamictal Tablet supplemental application incorporates by reference the clinical data contained in the Lamictal CD Chewable Tablet application so that the approved compressed tablet formulation can gain the new indication, as well. This cross-reference also allows for the development of one label for both lamotrigine products.

We have completed the review of these applications as submitted with draft labeling, and they are approvable. Before these applications may be approved, however, it will be necessary for you to respond to the following requests or comments.

Labeling

The attachment to this letter provides a draft of the labeling that the Agency asks you to adopt for Lamictal CD Chewable Dispersible Tablets and Lamictal Tablets upon approval of these applications. Although sections of this proposal are taken verbatim from the labeling proposed by you, other sections have been extensively revised and/or expanded to include new subsections. Please note that we have embedded throughout the text of the attached draft labeling, “Notes to Sponsor;”, requesting further revisions or clarification of the label, as well as blank spaces requiring a numeric value which you must provide.

If additional information relating to the safety or effectiveness of these drugs becomes available, revision of the labeling may be required.

Nomenclature

We have been advised by the CDER Labeling and Nomenclature Committee that the abbreviation “CD” has a large connection in the pharmaceutical community with sustained release dosage forms, and it is preferable that “CD” not appear as a suffix in the proprietary name of Lamictal Chewable Dispersible Tablets. Accordingly, we request that you adopt, as the proprietary name for the new dosage form of lamotrigine, Lamictal Chewable Dispersible Tablets. This request is reflected in the attached draft labeling.

Biopharmaceutics

1. Based on review of the data and rationale provided, your request for waiver of bioequivalence studies is granted for the Lamictal Chewable Dispersible Tablet, 25mg strength.
2. We ask that the following final dissolution methodology and specification be adopted for Lamictal Chewable Dispersible Tablets, 5mg, 25mg, and 100mg:

   Apparatus: USP Apparatus II (paddle)
   Agitation: 
   Medium: 0.1 N HCL, 900mL, 37 ± 0.5°C
   Specification: 

Chemistry, Manufacturing, and Controls

The expiration dating period for Lamictal Chewable Dispersible Tablets is 24 months when packaged and stored as per the original NDA submission.

Safety Update

Under 21 CFR 314.50(d)(5)(vi)(b), we request that you update your NDAs by submitting all safety information you now have regarding your new drugs. Please provide updated information as listed below:

1. Submit all safety data including results of trials that were still ongoing at the time of NDA submission. The presentation of this data can take the same form as in your initial submission. Tables comparing adverse reactions at the time the NDA was submitted now will certainly facilitate review.

2. Submit drop-outs with new drop-outs identified. Discuss, if appropriate.

3. Provide details of any significant changes or findings, if any.

4. Summarize worldwide experience on the safety of this drug.

5. Submit case report forms for each patient who died during a clinical study or who did not complete a study because of an adverse event.

Please also update the new drug applications with respect to reports of relevant safety information, including all deaths and any adverse events that led to discontinuation of the drug and any information suggesting a substantial difference in the rate of occurrence of common but less serious adverse events. The update should cover all studies and uses of the drug including: (1) those involving indications not being sought in the present submission, (2) other dosage forms, and (3) other dose levels, etc.
Promotional Material

In addition, please submit three copies of the introductory promotional material that you propose to use for these products. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional material and the package inserts directly to:

Food and Drug Administration
Division of Drug Marketing, Advertising and Communications
HFD-40
5600 Fishers Lane
Rockville, Maryland 20857

Within 10 days after the date of this letter, you are required to amend the applications, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of such action FDA may take action to withdraw the applications.

The drug may not be legally marketed until you have been notified in writing that the applications are approved.

If you have any questions, please contact Jacqueline H. Ware, Pharm.D., Regulatory Management Officer, at (301) 594-5793.

Sincerely,

/S/

Paul Leber, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research
NDA 20-764
NDA 20-241/S-002
Page 5

cc:
Original NDAs 20-764, 20-241
HFD-120/Div. Files
HFD-002/ORM
HFD-92/DDM-DIAP/ S/ 1/1/17 1/7/2017
HFD-120/J. Ware
HFD-120/Leber/Katz/Burkhardt/Fenney/Trestey/Fitzgerald/Aisar/Guzewski 24.97
HFD-710/Sahlroot/Wang
HFD-860/Sahajwallah/Tammara
HFD-101/Office Director
DISTRICT OFFICE
HFD-40/DDMAC (with draft labeling)
HFD-560/OTC (with labeling - for OTC Drug Products Only)

Drafted by: JHW/November 14, 1997/20764ae.ltr

Initialed by:
Final:

APPROVABLE (AE)
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 020764 and 020241/S002

FINAL PRINTED LABELING
SERIOUS RASHES REQUIRING HOSPITALIZATION AND DISCONTINUATION OF TREATMENT HAVE BEEN REPORTED IN ASSOCIATION WITH THE USE OF LAMICTAL. THE INCIDENCE OF THESE RASHES, WHICH HAVE INCLUDED STEVENS-JOHNSON SYNDROME, IS APPROXIMATELY 1% (1/100) IN PEDIATRIC PATIENTS (AGE <16 YEARS) AND 0.3% (3/1000) IN ADULTS. IN WORLDWIDE POSTMARKETING EXPERIENCE, RARE CASES OF TOXIC EPIDERMAL NECROLYSIS AND/OR RASH-RELATED DEATH HAVE BEEN REPORTED, BUT THEIR NUMBERS ARE TOO FEW TO PERMIT A PRECISE ESTIMATE OF THE RATE.

BECAUSE THE RATE OF SERIOUS RASH IS GREATER IN PEDIATRIC PATIENTS THAN IN ADULTS, IT BEARS EMphasis THAT LAMICTAL IS APPROVED ONLY FOR USE IN PEDIATRIC PATIENTS BELOW THE AGE OF 16 YEARS WHO HAVE SEIZURES ASSOCIATED WITH THE LENNOX-GASTAUT SYNDROME (SEE INDICATIONS).

OTHER THAN AGE, THERE ARE AS YET NO FACTORS IDENTIFIED THAT ARE KNOWN TO PREDICT THE RISK OF OCCURRENCE OR THE SEVERITY OF RASH ASSOCIATED WITH LAMICTAL. THERE ARE SUGGESTIONS, YET TO BE PROVEN, THAT THE RISK OF RASH MAY ALSO BE INCREASED BY 1) CO ADMINISTRATION OF LAMICTAL WITH VALPROIC ACID (VPA), 2) EXCEEDING THE RECOMMENDED INITIAL DOSE OF LAMICTAL, OR 3) EXCEEDING THE RECOMMENDED DOSE ESCALATION FOR LAMICTAL. HOWEVER, CASES HAVE BEEN REPORTED IN THE ABSENCE OF THESE FACTORS.

NEARLY ALL CASES OF LIFE-THREATENING RASHES ASSOCIATED WITH LAMICTAL HAVE OCCURRED WITHIN 2 TO 8 WEEKS OF TREATMENT INITIATION. HOWEVER, ISOLATED CASES HAVE BEEN REPORTED AFTER PROLONGED TREATMENT (E.G., 6 MONTHS). ACCORDINGLY, DURATION OF THERAPY CANNOT BE RELIED UPON AS A MEANS TO PREDICT THE POTENTIAL RISK HERALDED BY THE FIRST APPEARANCE OF A RASH.

ALTHOUGH BENIGN RASHES ALSO OCCUR WITH LAMICTAL, IT IS NOT POSSIBLE TO PREDICT RELIABLY WHICH RASHES WILL PROVE TO BE SERIOUS OR LIFE THREATENING. ACCORDINGLY, LAMICTAL SHOULD ORDINARILy BE DISCONTINUED AT THE FIRST SIGN OF RASH, UNLESS THE RASH IS CLEARLY NOT DRUG RELATED. DISCONTINUATION OF TREATMENT MAY NOT PREVENT A RASH FROM BECOMING LIFE THREATENING OR PERMANENTLY DISABLING OR DISFIGURING.
LAMICTAL® (lamotrigine) Tablets

DESCRIPTION: LAMICTAL (lamotrigine), an antiepileptic drug (AED) of the phenytoin class, is chemically unrelated to existing antiepileptic drugs. Its chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)-1H-indazole-1-carbonitrile (LDIC) and its molecular formula is C₁₅H₁₂Cl₂N₃O. Its molecular weight is 258.09.

Lamotrigine is a white to pale cream-colored powder and has a pKa of 5.7. Lamotrigine is very slightly soluble in water (0.17 mg/mL at 25°C) and slightly soluble in 0.1 M HCl (4.1 mg/mL at 25°C). The structural formula is:

```
\begin{center}
\includegraphics[width=0.5\textwidth]{structure.png}
\end{center}
```

LAMICTAL Tablets are supplied for oral administration as 25-mg (white), 100-mg (peach), 150-mg (cream), and 200-mg (blue) tablets. Each tablet contains the labeled amount of lamotrigine and the following inactive ingredients: lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate, FD&C Yellow No. 6 Lake (100-mg tablet only), ferric oxide, yellow (150-mg tablet only); and FD&C Blue No. 2 Lake (200-mg tablet only).

LAMICTAL Chewable Dispersible Tablets are supplied for oral administration. The tablets contain 5 mg (white), 25 mg (white), or 100 mg (white) of lamotrigine and the following inactive ingredients: blackcurrant flavor, calcium carbonate, low-substituted hydroxypropylcellulose, magnesium aluminum silicate, magnesium stearate, povidone, saccharin sodium, and sodium starch glycolate.

CLINICAL PHARMACOLOGY:

Mechanism of Action: The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. The relevance of these models to human epilepsy, however, is not known.

One proposed mechanism of action of LAMICTAL, the relevance of which remains to be established in humans, involves an effect on sodium channels. In vitro pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate).

Pharmacological Properties: Although the relevance for human use is unknown, the following data characterize the performance of LAMICTAL in receptor binding assays. Lamotrigine had a weak inhibitory effect on the serotonin 5-HT₃ receptor (IC₅₀ = 18 μM). It does not exhibit high affinity binding (IC₅₀≥100 μM) to the following neurotransmitter receptors: adenosine A₁, A₂, adrenergic α₁, α₂, and 3, dopamine D₁ and D₂, γ-aminobutyric acid (GABA) A and B, histamine H₁, kappa opioid.

2
LAMICTAL® (lamotrigine) Tablets

LAMICTAL® (lamotrigine) Chewable Dispersible Tablets

muscarnic acetylcholine, and serotonin 5-HT2. Studies have failed to detect an effect of lamotrigine on dicytrypyridine-sensitive calcium channels. It had weak effects at sigma opioid receptors (IC50 = 145 μM). Lamotrigine did not inhibit the uptake of norepinephrine, dopamine, serotonin, or aspartic acid (IC50 > 100 μM).

Effect of Lamotrigine on N-Methyl-d-Aspartate (NMDA)-Mediated Activity: Lamotrigine did not inhibit NMDA-induced depolarizations in rat cortical slices or NMDA-induced cyclic GMP formation in immature rat cerebellum, nor did lamotrigine displace compounds that are either competitive or noncompetitive ligands at this glutamate receptor complex (CNQX, CGS, TCUP). The IC50 for lamotrigine effects on NMDA-induced currents (in the presence of 3 μM glycine) in cultured hippocampal neurons exceeded 100 μM.

Folate Metabolism: In vitro, lamotrigine was shown to be an inhibitor of dihydrofolate reductase, the enzyme that catalyzes the reduction of dihydrofolate to tetrahydrofolate. Inhibition of this enzyme may interfere with the biosynthesis of nucleic acids and proteins. When oral daily doses of lamotrigine were given to pregnant rats during organogenesis, fetal, placental, and maternal folate concentrations were reduced. Significantly reduced concentrations of folate are associated with teratogenesis (see PRECAUTIONS. Pregnancy). Folate concentrations were also reduced in male rats given repeated oral doses of lamotrigine. Reduced concentrations were partially returned to normal when supplemented with folic acid.

Accumulation in Kidneys: Lamotrigine was found to accumulate in the kidney of the male rat, causing chronic progressive nephrosis, necrosis, and mineralization. These findings are attributed to α-2 microglobulin, a species- and sex-specific protein that has not been detected in humans or other animal species.

Melanin Binding: Lamotrigine binds to melanin-containing tissues, e.g., in the eye and pigmented skin. It has been found in the uveal tract up to 52 weeks after a single dose in rodents.

Cardiovascular: In dogs, lamotrigine is extensively metabolized to a 2-N-methyl metabolite. This metabolite causes dose-dependent prolongations of the PR interval, widening of the QRS complex, and, at higher doses, complete AV conduction block. Similar cardiovascular effects are not anticipated in humans because only trace amounts of the 2-N-methyl metabolite (<0.6% of lamotrigine dose) have been found in human urine (see Drug Disposition below). However, it is conceivable that plasma concentrations of this metabolite could be increased in patients with a reduced capacity to glucuronidate lamotrigine (e.g., in patients with liver disease).

Pharmacokinetics and Drug Metabolism: The pharmacokinetics of lamotrigine have been studied in patients with epilepsy, healthy young and elderly volunteers, and volunteers with chronic renal failure. Lamotrigine pharmacokinetic parameters for adult and pediatric patients and healthy normal volunteers are summarized in Tables 1 and 2.

3
<table>
<thead>
<tr>
<th>Adult Study Population</th>
<th>( t_{\text{max}} ) (h)</th>
<th>( t_{1/2} ) (h)</th>
<th>( Cl/F ) (ml/min/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patients taking enzyme-inducing antiepileptic drugs (EIAEDs)(^a)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose</td>
<td>24</td>
<td>2.3</td>
<td>14.4</td>
</tr>
<tr>
<td>LAMICTAL</td>
<td></td>
<td>(5.5-6.0)</td>
<td>(6.4-30.4)</td>
</tr>
<tr>
<td>Multiple-dose</td>
<td>17</td>
<td>2.0</td>
<td>12.6</td>
</tr>
<tr>
<td>LAMICTAL</td>
<td></td>
<td>(7.5-9.6)</td>
<td>(7.5-23.1)</td>
</tr>
<tr>
<td><strong>Patients taking EIAEDs + VPA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose</td>
<td>25</td>
<td>3.8</td>
<td>27.2</td>
</tr>
<tr>
<td>LAMICTAL</td>
<td></td>
<td>(1.0-10.0)</td>
<td>(11.2-51.6)</td>
</tr>
<tr>
<td><strong>Patients taking VPA only</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose</td>
<td>4</td>
<td>4.8</td>
<td>58.8</td>
</tr>
<tr>
<td>LAMICTAL</td>
<td></td>
<td>(1.8-8.4)</td>
<td>(20.5-88.8)</td>
</tr>
<tr>
<td><strong>Healthy volunteers taking VPA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose</td>
<td>6</td>
<td>1.8</td>
<td>48.3</td>
</tr>
<tr>
<td>LAMICTAL</td>
<td></td>
<td>(1.0-4.0)</td>
<td>(31.5-86.6)</td>
</tr>
<tr>
<td>Multiple-dose</td>
<td>19</td>
<td>1.9</td>
<td>70.3</td>
</tr>
<tr>
<td>LAMICTAL</td>
<td></td>
<td>(0.5-3.5)</td>
<td>(41.9-113.5)</td>
</tr>
<tr>
<td><strong>Healthy volunteers taking no other medications</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose</td>
<td>178</td>
<td>2.2</td>
<td>37.8</td>
</tr>
<tr>
<td>LAMICTAL</td>
<td></td>
<td>(0.25-12.0)</td>
<td>(14.0-103.0)</td>
</tr>
<tr>
<td>Multiple-dose</td>
<td>36</td>
<td>1.7</td>
<td>25.4</td>
</tr>
<tr>
<td>LAMICTAL</td>
<td></td>
<td>(0.5-4.0)</td>
<td>(11.6-61.6)</td>
</tr>
</tbody>
</table>

\(^a\)The majority of parameter means determined in each study had coefficients of variation between 20% and 40% for half-life and Cl/F and between 30% and 70% for \( t_{\text{max}} \). The overall mean values were calculated from individual study means that were weighted based on the number of volunteers/patients in each study. The numbers in parentheses below each parameter mean represent the range of individual volunteer/patient values across studies.

\(^a\)Examples of EIAEDs are carbamazepine, phenobarbital, phenytoin, and primidone.

The apparent clearance of lamotrigine is affected by the coadministration of AEDs.
Lamotrigine is eliminated more rapidly in patients who have been taking hepatic EIAEDs, including carbamazepine, phenytoin, phenobarbital, and primidone. Most clinical experience is derived from this population.

VPA, however, actually decreases the apparent clearance of lamotrigine (i.e., more than doubles the elimination half-life of lamotrigine), whether given with or without EIAEDs. Accordingly, if lamotrigine is to be administered to a patient receiving VPA, lamotrigine must be given at a reduced dosage, less than half the dose used in patients not receiving VPA (see DOSAGE AND ADMINISTRATION and PRECAUTIONS: Drug Interactions).

Absorption: Lamotrigine is rapidly and completely absorbed after oral administration with negligible first-pass metabolism (absolute bioavailability is 98%). The bioavailability is not affected by food. Peak plasma concentrations occur anywhere from 1.4 to 4.8 hours following drug administration. The lamotrigine chewable/dispensible tablets were found to be equivalent, whether they were administered as dispersed in water, chewed and swallowed, or swallowed as whole, to the lamotrigine compressed tablets in terms of rate and extent of absorption.

Distribution: Estimates of the mean apparent volume of distribution (Vd/F) of lamotrigine following oral administration ranged from 0.9 to 1.3 L/kg. Vd/F is independent of dose and is similar following single and multiple doses in both patients with epilepsy and in healthy volunteers.

Protein Binding: Data from in vitro studies indicate that lamotrigine is approximately 55% bound to human plasma proteins at plasma lamotrigine concentrations from 1 to 10 mg/mL, 10 mg/mL, or four to six times the trough plasma concentration observed in the controlled efficacy trials. Because lamotrigine is not highly bound to plasma proteins, clinically significant interactions with other drugs through competition for protein binding sites are unlikely. The binding of lamotrigine to plasma proteins did not change in the presence of therapeutic concentrations of phenytoin, phenobarbital, or VPA. Lamotrigine did not displace other AEDs (carbamazepine, phenytoin, phenobarbital) from protein binding sites.

Drug Disposition: Lamotrigine is metabolized predominantly by glucuronic acid conjugation, the major metabolite is an inactive 2-N-glucuronide conjugate. After oral administration of 240 mg of 14C-lamotrigine (15 μCi) to six healthy volunteers, 94% was recovered in the urine and 2% was recovered in the feces. The radioactivity in the urine consisted of unchanged lamotrigine (10%), the 2-N-glucuronide (76%), a 5-N-glucuronide (10%), a 2-N-methylnicotinol (0.14%), and other unidentified minor metabolites (4%).

Enzyme Induction: The effects of lamotrigine on specific families of mixed-function oxidase enzymes have not been systematically evaluated. Following multiple administrations (150 mg twice daily) to normal volunteers taking no other medications, lamotrigine induced its own metabolism, resulting in a 25% decrease in T1/2 and a 37% increase in CL/F at steady state compared to values obtained in the same volunteers following a single dose. Evidence gathered from other sources suggests that self-induction by LAMICTAL may not occur when LAMICTAL is given as adjunctive therapy in patients receiving EIAEDs.

Dose Proportionality: In healthy volunteers not receiving any other medications and given single
doses, the plasma concentrations of lamotrigine increased in direct proportion to the dose administered over the range of 50 to 400 mg. In two small studies (n = 7 and 8) of patients with epilepsy who were maintained on other AEDs, there also was a linear relationship between dose and lamotrigine plasma concentrations at steady state following doses of 50 to 350 mg twice daily.

Elimination: (See Table 1)

Special Populations: Patients With Renal Insufficiency: Twelve volunteers with chronic renal failure (mean creatinine clearance = 13 mL/min; range, 6 to 23) and another six individuals undergoing hemodialysis were each given a single 100-mg dose of LAMICTAL. The mean plasma half-lives determined in the study were 42.9 hours (chronic renal failure), 13.0 hours (during hemodialysis), and 57.4 hours (between hemodialyses) compared to 26.2 hours in healthy volunteers. On average, approximately 20% (range = 5.6 to 35.1) of the amount of lamotrigine present in the body was eliminated by hemodialysis during a 4-hour session.

Hepatic Disease: The pharmacokinetic parameters of lamotrigine in patients with impaired liver function have not been studied.

Age: Pediatric Patients: The pharmacokinetics of LAMICTAL following a single 2-mg/kg dose were evaluated in two studies of pediatric patients with epilepsy (n = 25 for patients aged 10 months to 5.3 years and n = 19 for patients aged 5 to 11 years). All patients were receiving concomitant therapy with other AEDs. Lamotrigine pharmacokinetic parameters for pediatric patients are summarized in Table 2.

As with adults, the elimination of lamotrigine in pediatric patients was similarly affected by concomitant AEDs. Weight-normalized oral clearance (Cl/F) was higher (on the order of thirds) in infants and children (age 10 months to 11 years) than in the adolescents and adults, while adolescents and adults had similar mean values of Cl/F.
<table>
<thead>
<tr>
<th>Ages 10 months-5.3 years</th>
<th>Number of Subjects</th>
<th>f1 (h)</th>
<th>f2 (h)</th>
<th>Cmax (mL/min/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients taking EIAEDs</td>
<td>10</td>
<td>3.0</td>
<td>7.7</td>
<td>3.62</td>
</tr>
<tr>
<td>(1.0-5.9)</td>
<td>(5.7-11.4)</td>
<td>(2.44-5.28)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients taking AEDs with no known effect on drug-metabolizing enzymes</td>
<td>7</td>
<td>5.2</td>
<td>19.0</td>
<td>1.2</td>
</tr>
<tr>
<td>(2.9-6.1)</td>
<td>(12.8-27.1)</td>
<td>(0.75-2.42)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients taking VPA only</td>
<td>8</td>
<td>2.9</td>
<td>44.9</td>
<td>0.47</td>
</tr>
<tr>
<td>(1.0-6.0)</td>
<td>(29.5-52.5)</td>
<td>(0.23-0.77)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ages 5-11 years</th>
<th>Number of Subjects</th>
<th>f1 (h)</th>
<th>f2 (h)</th>
<th>Cmax (mL/min/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients taking EIAEDs</td>
<td>7</td>
<td>1.6</td>
<td>7.0</td>
<td>2.54</td>
</tr>
<tr>
<td>(1.0-3.0)</td>
<td>(3.6-9.8)</td>
<td>(1.35-5.58)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients taking EIAEDs plus VPA</td>
<td>8</td>
<td>3.3</td>
<td>19.1</td>
<td>0.80</td>
</tr>
<tr>
<td>(1.0-6.4)</td>
<td>(7.0-31.2)</td>
<td>(0.35-1.83)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients taking VPA only*</td>
<td>3</td>
<td>4.5</td>
<td>85.8</td>
<td>0.24</td>
</tr>
<tr>
<td>(3.0-6.0)</td>
<td>(50.7-73.7)</td>
<td>(0.21-0.26)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ages 13-18 years</th>
<th>Number of Subjects</th>
<th>f1 (h)</th>
<th>f2 (h)</th>
<th>Cmax (mL/min/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients taking EIAEDs</td>
<td>11</td>
<td>1</td>
<td>1</td>
<td>1.3</td>
</tr>
<tr>
<td>Patients taking EIAEDs plus VPA</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
</tr>
<tr>
<td>Patients taking VPA only</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>0.3</td>
</tr>
</tbody>
</table>

*Two subjects were included in the calculation for mean f1\_max.

**Parameter not estimated.

**Elderly:** In a single-dose study (150 mg of LAMICTAL), the pharmacokinetics of lamotrigine in 12 elderly volunteers between the ages of 65 and 76 years (mean creatinine clearance = 61 mL/min, range = 33 to 108) were similar to those of young, healthy volunteers in other studies.

**Gender:** The clearance of lamotrigine is not affected by gender.

**Race:** The apparent oral clearance of lamotrigine was 25% lower in non-Caucasians than Caucasians.

**CLINICAL STUDIES:** The results of controlled clinical trials established the efficacy of LAMICTAL as adjunctive therapy in adults with partial seizures and as adjunctive therapy in the generalized seizures of Lennox-Gastaut syndrome in pediatric and adult patients.

**Adjunctive Therapy With LAMICTAL In Adulta:** The effectiveness of LAMICTAL as adjunctive therapy (added to other AEDs) was established in three multicenter, placebo-controlled, double-blind...
clinical trials in 355 adults with refractory partial seizures. The patients had a history of at least four partial seizures per month in spite of receiving one or more AEDs at therapeutic concentrations and, in two of the studies, were observed on their established AED regimen during baselines that varied between 8 to 12 weeks. In the third, patients were not observed in a prospective baseline. In patients continuing to have at least four seizures per month during the baseline, LAMICTAL or placebo was then added to the existing therapy. In all three studies, change from baseline in seizure frequency was the primary measure of effectiveness. The results given below are for all partial seizures in the intent-to-treat population (all patients who received at least one dose of treatment) in each study, unless otherwise indicated. The median seizure frequency at baseline was 3 per week while the mean at baseline was 6.6 per week for all patients enrolled in efficacy studies.

One study (n = 216) was a double-blind, placebo-controlled, parallel trial consisting of a 24-week treatment period. Patients could not be on more than two other anticonvulsants and VPA was not allowed. Patients were randomized to receive placebo, a target dose of 300 mg/day of LAMICTAL, or a target dose of 500 mg/day of LAMICTAL. The median reductions in the frequency of all partial seizures relative to baseline were 6% in patients receiving placebo, 20% in patients receiving 300 mg/day of LAMICTAL, and 36% in patients receiving 500 mg/day of LAMICTAL. The seizure frequency reduction was statistically significant in the 500-mg/day group compared to the placebo group, but not in the 300-mg/day group.

A second study (n = 88) was a double-blind, placebo-controlled, randomized, crossover trial consisting of two 14-week treatment periods (the last 2 weeks of which consisted of dose tapering) separated by a 4-week washout period. Patients could not be on more than two other anticonvulsants and VPA was not allowed. The target dose of LAMICTAL was 400 mg/day. When the first 12 weeks of treatment periods were analyzed, the median change in seizure frequency was a 25% reduction on LAMICTAL compared to placebo (P<0.01).

The third study (n = 41) was a double-blind, placebo-controlled, crossover trial consisting of two 12-week treatment periods separated by a 4-week washout period. Patients could not be on more than two other anticonvulsants. Thirteen patients were on concomitant VPA, these patients received 150 mg/day of LAMICTAL. The 28 other patients had a target dose of 300 mg/day of LAMICTAL. The median change in seizure frequency was a 28% reduction on LAMICTAL compared to placebo (P=0.01).

No differences in efficacy based on age, sex, or race, as measured by change in seizure frequency, were detected.

Adjuvantive Therapy With LAMICTAL: In Pediatric and Adult Patients With Lennox-Gastaut Syndrome: The effectiveness of LAMICTAL as an adjuvant therapy in patients with Lennox-Gastaut syndrome was established in a multicenter, double-blind, placebo-controlled trial in 159 patients aged 3 to 25 years (n = 79 on LAMICTAL, n = 80 on placebo). Following a 4-week single-blind, placebo phase, patients were randomized to 16 weeks of treatment with LAMICTAL or placebo added to their current AED regimen of up to three drugs. Patients were dosed on a fixed-dose regimen based on body weight and VPA use. Target doses were designed to approximate 5 mg/kg per day for patients.
LAMICTAL® (lamotrigine) Tablets

INDICATIONS AND USAGE: LAMICTAL is indicated as adjunctive therapy in adults with partial seizures and as adjunctive therapy in the generalized seizures of Lennox-Gastaut syndrome in pediatric and adult patients. Safety and effectiveness in patients below the age of 16 other than those with Lennox-Gastaut syndrome have not been established (see BOX WARNING).

CONTRAINDICATIONS: LAMICTAL is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.

WARNINGS: SEE BOX WARNING REGARDING THE RISK OF SERIOUS RASHES REQUIRING HOSPITALIZATION AND DISCONTINUATION OF LAMICTAL.

ALTHOUGH BENIGN RASHES ALSO OCCUR WITH LAMICTAL, IT IS NOT POSSIBLE TO PREDICT RELIABLY WHICH RASHES WILL PROVE TO BE SERIOUS OR LIFE THREATENING. ACCORDINGLY, LAMICTAL SHOULD ORDINARILY BE DISCONTINUED AT THE FIRST SIGN OF RASH, UNLESS THE RASH IS CLEARLY NOT DRUG RELATED. DISCONTINUATION OF TREATMENT MAY NOT PREVENT A RASH FROM BECOMING LIFE THREATENING OR PERMANENTLY DISABLING OR DISFIGURING.

Serious Rash: Pediatric Population: The incidence of serious rash associated with hospitalization and discontinuation of LAMICTAL in a prospectively followed cohort of pediatric patients was approximately 1.1% (14/1233). When these 14 cases were reviewed by 3 expert dermatologists, there was considerable disagreement as to their proper classification. To illustrate, one dermatologist considered none of the cases to be Stevens-Johnson syndrome, another assigned 7 of the 14 to this diagnosis. There were no deaths or permanent sequelae in these patients. Additionally, there have been rare cases of toxic epidermal necrolysis with and without permanent sequelae and death in US and foreign postmarketing experience. It bears emphasis, accordingly, that LAMICTAL is only approved for use in those patients below the age of 16 who have seizures associated with the Lennox-Gastaut syndrome (see INDICATIONS).

Because foreign postmarketing reports suggested that the rate of serious rash was greater with concomitant VPA use and because metabolism of LAMICTAL is inhibited by VPA, resulting in increased LAMICTAL plasma levels, the drug development database was examined for concomitant VPA use in pediatric patients who used VPA concomitantly. 1.1% (5/443) experienced a serious rash compared to 1.1% (6/529) patients not taking VPA. Although the numbers are small, 1.7% (5/294).
patients taking either VPA alone or VPA + non-EIAEDs experienced a serious rash compared to 0% (0/149) patients taking VPA + EIAEDs.

Adult Population: Serious rash associated with hospitalization and discontinuation of LAMICTAL occurred in 0.3% (11/3348) of patients who received LAMICTAL in premarketing clinical trials. No fatalities occurred among these individuals. However, in worldwide postmarketing experience, rare cases of rash-related death have been reported, but their numbers are too few to permit a precise estimate of the rate.

Among the rashes leading to hospitalization were Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, and a rash associated with a variable number of the following systemic manifestations: fever, lymphadenopathy, facial swelling, hematologic, and hepatic abnormalities.

There is evidence that the inclusion of VPA in a mult drug regimen increases the risk of serious, potentially life-threatening rash in adults. Specifically, of 394 patients administered LAMICTAL with VPA in clinical trials, 9 (1%) were hospitalized in association with rash; in contrast, 4 (0.16%) of 2398 clinical trial patients and volunteers administered LAMICTAL in the absence of VPA were hospitalized.

Other examples of serious and potentially life-threatening rash that did not lead to hospitalization also occurred in premarketing development. Among these, one case was reported to be Stevens-Johnson-like.

Hypersensitivity Reactions: Hypersensitivity reactions, some fatal or life threatening, have also occurred. Some of these reactions have included clinical features of multiorgan dysfunction such as hepatic abnormalities and evidence of disseminated intravascular coagulation. It is important to note that early manifestations of hypersensitivity (e.g., fever, lymphadenopathy) may be present even though a rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. LAMICTAL should be discontinued if an alternative etiology for the signs or symptoms cannot be established.

Prior to initiation of treatment with LAMICTAL, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately.

Acute Multiorgan Failure: Fatalities associated with multiorgan failure and various degrees of hepatic failure have been reported in 23706 adult patients and 31136 pediatric patients who received LAMICTAL during premarketing clinical trials. Rare fatalities from multiorgan failure have also been reported in compassionate use and postmarketing use. All of these cases occurred in association with other serious medical events (e.g., status epilepticus, overwhelming sepsis), making it impossible to identify the initiating cause.

Additionally, three patients (a 45-year-old woman, a 3.5-year-old boy, and an 11-year-old girl) developed multiorgan dysfunction and disseminated intravascular coagulation 9 to 14 days after LAMICTAL was added to their AED regimens. Rash and elevated transaminases were also present in all patients and rhabdomyolysis was noted in two patients. Both pediatric patients were receiving
LAMICTAL® (lamotrigine) Tablets

Concomitant therapy with VPA, while the adult patient was being treated with carbamazepine and concomitant therapy with VPA, while the adult patient was being treated with carbamazepine and

Withdrawal Seizures: As a rule, AEDs should not be abruptly discontinued because of the possibility of increasing seizure frequency. Unless safety concerns require a more rapid withdrawal, the dosage of LAMICTAL should be tapered over a period of at least 2 weeks (see DOSAGE AND ADMINISTRATION).

Special Dosing Considerations for Pediatric Patients: The lowest available strength of LAMICTAL Chewable Dispensable Tablets is 5 mg, and only whole tablets should be administered. Since the dosage of LAMICTAL in pediatric patients is based on body weight and the lowest tablet strength is 5 mg, some low-weight pediatric patients should not receive LAMICTAL. Specifically, pediatric patients who weigh less than 17 kg (37 lbs) should not receive LAMICTAL because therapy cannot be initiated using the dosing guidelines and the currently available tablet strengths (see DOSAGE AND ADMINISTRATION).

PRECAUTIONS:

Dermatological Events (see BOX WARNING, WARNINGS): Serious rashes associated with hospitalization and discontinuation of LAMICTAL have been reported. Rare deaths have been reported, but their numbers are too few to permit a precise estimate of the rate. There are suggestions, yet to be proven, that the risk of rash may also be increased by 1) coadministration of LAMICTAL with VPA, 2) exceeding the recommended initial dose of LAMICTAL, or 3) exceeding the recommended dose escalation for LAMICTAL. However, cases have been reported in the absence of these factors.

In clinical trials, approximately 10% of all patients exposed to LAMICTAL developed a rash. Rashes associated with LAMICTAL do not appear to have unique identifying features. Typically, rash occurs in the first 2 to 8 weeks following treatment initiation. However, isolated cases have been reported after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as a means to predict the potential risk heralded by the first appearance of a rash.

Although most rashes resolved even with continuation of treatment with LAMICTAL, it is not possible to predict reliably which rashes will prove to be serious or life threatening. ACCORDINGLY, LAMICTAL SHOULD ORDINARILY BE DISCONTINUED AT THE FIRST SIGN OF RASH.
Sudden Unexplained Death in Epilepsy (SUDEP): During the premarketing development of LAMICTAL, 20 sudden and unexplained deaths were recorded among a cohort of 4700 patients with epilepsy (5747 patient-years of exposure).

Some of these could represent seizure-related deaths in which the seizure was not observed, e.g., at night. This represents an incidence of 0.0036 deaths per patient-year. Although this rate exceeds that expected in a healthy population matched for age and sex, it is within the range of estimates for the incidence of sudden unexplained deaths in patients with epilepsy not receiving LAMICTAL (ranging from 0.0005 for the general population of patients with epilepsy, to 0.004 for a recently studied clinical trial population similar to that in the clinical development program for LAMICTAL, to 0.005 for patients with refractory epilepsy). Consequently, whether these figures are reassuring or suggest concern depends on the comparability of the populations reported upon to the cohort receiving LAMICTAL and the accuracy of the estimates provided. Probably most reassuring is the similarity of estimated SUDEP rates in patients receiving LAMICTAL and those receiving another antiepileptic drug that underwent clinical testing in a similar population at about the same time. Importantly, that drug is chemically unrelated to LAMICTAL. This evidence suggests although it certainly does not prove, that the high SUDEP rates reflect population rates, not a drug effect.

Status Epilepticus: Valid estimates of the incidence of treatment emergent status epilepticus among patients treated with LAMICTAL are difficult to obtain because reporters participating in clinical trials did not all employ identical rules for identifying cases. At a minimum, 7 of 2343 adult patients had episodes that could unequivocally be described as status. In addition, a number of reports of variably defined episodes of seizure exacerbation (e.g., seizure clusters, seizure flurries, etc.) were made.

Addition of LAMICTAL to a Multidrug Regimen That Includes VPA (Doseage Reduction): Because VPA reduces the clearance of lamotrigine, the dosage of lamotrigine in the presence of VPA is less than half of that required in its absence (see DOSAGE AND ADMINISTRATION).

Use in Patients With Concomitant Illness: Clinical experience with LAMICTAL in patients with concomitant illness is limited. Caution is advised when using LAMICTAL in patients with diseases or conditions that could affect metabolism or elimination of the drug, such as renal, hepatic, or cardiac functional impairment.

Hepatic metabolism to the glucuronide followed by renal excretion is the principal route of elimination of lamotrigine (see CLINICAL PHARMACOLOGY).

A study in individuals with severe chronic renal failure (mean creatinine clearance = 13 mL/min) not receiving other AEDs indicated that the elimination half-life of unchanged lamotrigine is prolonged relative to individuals with normal renal function. Until adequate numbers of patients with severe renal impairment have been evaluated during chronic treatment with LAMICTAL, it should be used with caution in these patients, generally using a reduced maintenance dose for patients with significant impairment.
Because there is no experience with the use of LAMICTAL in patients with impaired liver function, the use in such patients may be associated with as yet unrecognized risks.

Binding in the Eye and Other Melanin-Containing Tissues: Because lamotrigine binds to melanin, it could accumulate in melanin-rich tissues over time. This raises the possibility that lamotrigine may cause toxicity in these tissues after extended use. Although ophthalmological testing was performed in one controlled clinical trial, the testing was inadequate to exclude subtle effects or injury occurring after long-term exposure. Moreover, the capacity of available tests to detect potentially adverse consequences, if any, of lamotrigine's binding to melanin is unknown.

Accordingly, although there are no specific recommendations for periodic ophthalmological monitoring, prescribers should be aware of the possibility of long-term ophthalmological effects.

Information for Patients: Prior to initiation of treatment with LAMICTAL, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately. In addition, the patient should notify his physician if worsening of seizure control occurs.

Patients should be advised that LAMICTAL may cause dizziness, somnolence, and other symptoms and signs of central nervous system (CNS) depression. Accordingly, they should be advised neither to drive a car nor to operate other complex machinery until they have gained sufficient experience on LAMICTAL to gauge whether or not it adversely affects their mental and/or motor performance.

Patients should be advised to notify their physicians if they become pregnant or intend to become pregnant during therapy. Patients should be advised to notify their physicians if they intend to breast-feed or are breast-feeding an infant.

Patients should be informed of the availability of a patient information leaflet, and they should be instructed to read the leaflet prior to taking LAMICTAL. See PATIENT INFORMATION at the end of this labeling for the text of the leaflet provided for patients.

Laboratory Tests: The value of monitoring plasma concentrations of LAMICTAL has not been established. Because of the possible pharmacokinetic interactions between LAMICTAL and other AEDs being taken concomitantly (see Table 3), monitoring of the plasma levels of LAMICTAL and concomitant AEDs may be indicated, particularly during dosage adjustments. In general, clinical judgment should be exercised regarding monitoring of plasma levels of LAMICTAL and other anti-seizure drugs and whether or not dosage adjustments are necessary.

Drug Interactions: Antiepileptic Drugs: The use of AEDs in combination is complicated by the potential for pharmacokinetic interactions.

The interaction of lamotrigine with phenytoin, carbamazepine, and VPA has been studied. The net effects of these various AED combinations on individual AED plasma concentrations are summarized in Table 3.
## Table 3: Summary of AED Interactions With LAMICTAL

<table>
<thead>
<tr>
<th>AED</th>
<th>Lamotrigine Plasma Concentration With Adjunctive LAMICTAL&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Lamotrigine Plasma Concentration With Adjunctive AEDs&lt;sup&gt;2&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenytoin (PHT)</td>
<td>++</td>
<td>↓</td>
</tr>
<tr>
<td>Carbamazepine (CBZ)</td>
<td>++</td>
<td>↓&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>CBZ epoxide&lt;sup&gt;4&lt;/sup&gt;</td>
<td>?</td>
<td>↑</td>
</tr>
<tr>
<td>Valproic acid (VPA)</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>VPA + PHT and/or CBZ</td>
<td>NE</td>
<td>++</td>
</tr>
</tbody>
</table>

<sup>1</sup> From adjunctive clinical trials and volunteer studies.

<sup>2</sup> Net effects were estimated by comparing the mean clearance values obtained in adjunctive clinical trials and volunteers studies.

<sup>3</sup> Not administered, but an active metabolite of carbamazepine.

<sup>4</sup> = No significant effect.

<sup>5</sup> = Conflicting data.

NE = not evaluated.

### Specific Effects of Lamotrigine on the Pharmacokinetics of Other AED Products:

**LAMICTAL Added to Phenytoin:** LAMICTAL has no appreciable effect on steady-state phenytoin plasma concentration.

**LAMICTAL Added to Carbamazepine:** LAMICTAL has no appreciable effect on steady-state carbamazepine plasma concentration. Limited clinical data suggest there is a higher incidence of dizziness, diplopia, ataxia, and blurred vision in patients receiving carbamazepine with LAMICTAL, than in patients receiving other EIAEDs with LAMICTAL (see ADVERSE REACTIONS). The mechanism of this interaction is unclear. The effect of lamotrigine on plasma concentrations of carbamazepine-epoxide is unclear. In a small subset of patients (n = 7) studied in a placebo-controlled trial, lamotrigine had no effect on carbamazepine-epoxide plasma concentrations, but in a small, uncontrolled study (n = 9), carbamazepine-epoxide levels were seen to increase.

**LAMICTAL Added to VPA:** When LAMICTAL was administered to 18 healthy volunteers receiving VPA in a pharmacokinetic study, the trough steady-state VPA concentrations in plasma decreased by an average of 25% over a 3-week period, and then stabilized. However, adding LAMICTAL to the existing therapy did not cause a change in plasma VPA concentrations in either adult or pediatric patients in controlled clinical trials.

**Specific Effects of Other AED Products on the Pharmacokinetics of Lamotrigine: Phenytoin Added to LAMICTAL:** The addition of phenytoin decreases lamotrigine steady-state concentrations by approximately 45% to 54% depending upon the total daily dose of phenytoin (i.e., from 100 to 400 mg).

**Carbamazepine Added to LAMICTAL:** The addition of carbamazepine decreases lamotrigine steady-state concentrations by approximately 40%.
Carcinogenesis, Mutagenesis, Impairment of Fertility: No evidence of carcinogenicity was seen in one mouse study or two rat studies following oral administration of lamotrigine for up to 2 years at maximum tolerated doses (30 mg/kg per day for mice and 10 to 15 mg/kg per day for rats, doses that are equivalent to 90 mg/m² and 60 to 90 mg/m², respectively). Steady-state plasma concentrations ranged from 1 to 4 mcg/mL in the mouse study and 1 to 10 mcg/mL in the rat study. Plasma concentrations associated with the recommended human doses of 300 to 500 mg/day are generally in the range of 2 to 6 mcg/mL, but concentrations as high as 19 mcg/mL have been recorded.

Lamotrigine was not mutagenic in the presence or absence of metabolic activation when tested in two gene mutation assays (the Ames test and the in vitro mammalian mouse lymphoma assay). In two cytogenetic assays (the in vitro human lymphocyte assay and the in vivo rat bone marrow assay), lamotrigine did not increase the incidence of structural or numerical chromosomal abnormalities.

No evidence of impairment of fertility was detected in rats given oral doses of lamotrigine up to 2.4 times the highest usual human maintenance dose of 33 mg/kg per day or 0.4 times the human dose on a mg/m² basis. The effect of lamotrigine on human fertility is unknown.

Pregnancy: Pregnancy Category C. No evidence of teratogenicity was found in mice, rats, or rabbits when lamotrigine was orally administered to pregnant animals during the period of organogenesis at doses up to 1,2, 0.5, and 11 times, respectively, on a mg/m² basis, the highest usual human maintenance dose (i.e., 500 mg/day). However, maternal toxicity and secondary fetal toxicity producing reduced fetal weight and/or delayed ossification were seen in mice and rats, but not in rabbits at these doses. Teratology studies were also conducted using bolus intravenous administration of the oxethionate salt of lamotrigine in rats and rabbits. In rat dams administered an intravenous dose at 0.6 times the highest usual human maintenance dose, the incidence of intrauterine death without signs of teratogenicity was increased.

A behavioral teratology study was conducted in rats dosed during the period of organogenesis. At day 21 postpartum, offspring of dams receiving 5 mg/kg per day or higher displayed a significantly longer latent period for open field exploration and a lower frequency of rearing. In a swimming maze test performed on days 39 to 44 postpartum, time to completion was increased in offspring of dams receiving 25 mg/kg per day. These doses represent 0.1 and 0.5 times the clinical dose on a mg/m² basis, respectively.

Lamotrigine did not affect fertility, teratogenesis, or postnatal development when rats were dosed.
NDA 20-764; Lamictal Chewable Dispersible Tablets
NDA 20-241/S-002; Lamictal Tablets
LAMICTAL® (lamotrigine) Tablets
LAMICTAL® (lamotrigine) Chewable Dispersible Tablets
prior to and during mating, and throughout gestation and lactation at doses equivalent to 0.4 times
the highest usual human maintenance dose on a mg/m² basis.
When pregnant rats were orally dosed at 0.1, 0.5, 1.4, or 0.3 times the highest human maintenance
dose (on a mg/m² basis) during the latter part of gestation (days 15 to 20), maternal toxicity and fetal
death were seen. In dams, food consumption and weight gain were reduced, and the gestation period
was slightly prolonged (22.5 vs. 22.0 days in the control group). Stillborn pups were found in all three
drug-treated groups with the highest number in the high-dose group. Postnatal death was also seen,
but only in the two highest doses, and occurred between day 1 and 20. Some of these deaths appear
to be drug-related and not secondary to the maternal toxicity. A no-observed-effect level (NOEL)
could not be determined for this study.
Although LAMICTAL was not found to be teratogenic in the above studies, lamotrigine decreases
fetal bile concentrations in rats, an effect known to be associated with teratogenesis in animals and
humans. There are no adequate and well-controlled studies in pregnant women. Because animal
reproduction studies are not always predictive of human response, this drug should be used during
pregnancy only if the potential benefit justifies the potential risk to the fetus.
Pregnancy Exposure Registry: To facilitate monitoring fetal outcomes of pregnant women exposed
to lamotrigine, physicians are encouraged to register patients, before fetal outcome (e.g.,
ultrasound, results of amniocentesis, birth, etc.) is known, in the Antiepileptic Drug Pregnancy
Registry by calling (888) 233-2334 (toll free).
Labor and Delivery: The effect of LAMICTAL on labor and delivery in humans is unknown.
Use in Nursing Mothers: Preliminary data indicate that lamotrigine passes into human milk.
Because the effects on the infant exposed to LAMICTAL by this route are unknown, breast-feeding
while taking LAMICTAL is not recommended.
Pediatric Use: In pediatric patients, LAMICTAL is only indicated as adjunctive therapy for the
generalized seizures of Lennox-Gastaut syndrome. Safety and effectiveness for other uses in
patients below the age of 16 years have not been established (see BOX WARNING).
Geriatric Use: Because few patients over the age of 65 (approximately 20) were exposed to
LAMICTAL during its premarket evaluation, no specific statements about the safety or effectiveness
of LAMICTAL in this age-group can be made.

ADVERSE REACTIONS: SERIOUS RASH REQUIRING HOSPITALIZATION AND
DISCONTINUATION OF LAMICTAL, INCLUDING STEVENS-JOHNSON SYNDROME AND TOXIC
EPIDERMAL NECROLYSIS, HAVE OCCURRED IN ASSOCIATION WITH THERAPY WITH
LAMICTAL. RARE DEATHS HAVE BEEN REPORTED, BUT THEIR NUMBERS ARE TOO FEW
TO PERMIT A PRECISE ESTIMATE OF THE RATE (see BOX WARNING).
Adverse Events in Adults: Adjunctive Therapy for Partial Seizures: The most commonly
observed adverse experiences seen in association with LAMICTAL during adjunctive therapy in
adults and not seen at an equivalent frequency among placebo-treated patients, were dizziness,
slurred speech, somnolence, headache, diplopia, blurred vision, nausea, vomiting, and rash. Dizziness,
diplopia, ataxia, blurred vision, nausea, and vomiting were dose related. Dizziness, diplopia, ataxia, and blurred vision occurred more commonly in patients receiving carbamazepine with LAMICTAL than in patients receiving other EIAEDs with LAMICTAL. Clinical data suggest a higher incidence of rash, including serious rash, in patients receiving concomitant VPA than in patients not receiving VPA (see WARNINGS).

Approximately 11% of the 4932 individuals who received LAMICTAL in premarketing clinical trials discontinued treatment because of an adverse experience. The adverse events most commonly associated with discontinuation were: rash (3.4%), dizziness (2.2%), and headache (2.2%).

In a dose response study in adults, the rate of discontinuation of LAMICTAL for dizziness, ataxia, diplopia, blurred vision, nausea, and vomiting was dose related.

Incidence in Controlled Adjunctive Clinical Studies in Adults: The prescriber should be aware that the figures in Tables 4 and 5, obtained when LAMICTAL was added to concurrent AED therapy, cannot be used to predict the frequency of adverse experiences in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments, uses, or investigators. An inspection of these frequencies, however, does provide the prescriber with one basis to estimate the relative contribution of drug and nondrug factors to the adverse event incidences in the population studied.

Table 4 lists treatment-emergent signs and symptoms that occurred in at least 1% of adult patients with epilepsy treated with LAMICTAL in placebo-controlled trials and were numerically more common in the patients treated with LAMICTAL. In these studies, either LAMICTAL or placebo was added to the patient's current AED therapy. Adverse events were usually mild to moderate in intensity.

| Table 4: Treatment-Emergent Adverse Event Incidence in Adults in Placebo-Controlled Adjunctive Trials* (Events in at least 1% of patients treated with LAMICTAL and numerically more frequent than in the placebo group) |
|---|---|---|
| Body System | Percent of Patients Receiving Adjunctive LAMICTAL (%) (n = 711) | Percent of Patients Receiving Adjunctive Placebo (%) (n = 419) |
| Body as a whole | | |
| Headache | 29 | 19 |
| Flu syndrome | 7 | 5 |
| Fever | 6 | 4 |
| Abdominal pain | 5 | 4 |
| Neck pain | 2 | 1 |
| Reaction aggravated | 2 | 1 |

17
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td></td>
<td>Hot rashes</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>18</td>
</tr>
<tr>
<td>Digestive</td>
<td></td>
<td>Nausea</td>
<td>19</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vomiting</td>
<td>9</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diarrhea</td>
<td>6</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dyspepsia</td>
<td>5</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Constipation</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tooth disorder</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anorexia</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dry mouth</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td></td>
<td>Antralgia</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Myasthenia</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Nervous</td>
<td></td>
<td>Dizziness</td>
<td>38</td>
<td>13</td>
<td>13</td>
<td>13</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ataxia</td>
<td>22</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Somnolence</td>
<td>14</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Incoordination</td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Insomnia</td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tremor</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Depression</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anxiety</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Convulsion</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Irritability</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Speech disorder</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Concentration disturbance</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Emotional lability</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vertigo</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dysarthria</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Muscle spasm</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory</td>
<td></td>
<td>Rhinitis</td>
<td>14</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharyngitis</td>
<td>10</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cough increased</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dyspnea</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Skin and appendages</td>
<td></td>
<td>Rash</td>
<td>10</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pruritus</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>
Special senses
- Diplopia: 28 (n = 355) vs. 7 (n = 207)
- Blurred vision: 16 (n = 355) vs. 5 (n = 207)
- Vision abnormality: 3 (n = 355) vs. 1 (n = 207)

Urogenital
- Female patients only: 7 (n = 355) vs. 6 (n = 207)
- Dysmenorrhea: 7 (n = 355) vs. 6 (n = 207)
- Vaginitis: 4 (n = 355) vs. 1 (n = 207)
- Amenorrhea: 2 (n = 355) vs. 1 (n = 207)

*Patients in these additive studies were receiving one to three concomitant EIAEDs in addition to LAMICTAL or placebo. Patients may have reported multiple adverse experiences during the study or at discontinuation; thus, patients may be included in more than one category.

†Adverse experiences reported by at least 1% of patients treated with LAMICTAL are included.

In a randomized, parallel study comparing placebo and 300 and 500 mg/day of LAMICTAL, some of the more common drug-related adverse events were dose related (see Table 5).

Table 5: Dose-Related Adverse Events From a Randomized, Placebo-Controlled Trial in Adults

<table>
<thead>
<tr>
<th>Percent of Patients Experiencing Adverse Experiences</th>
<th>Placebo (n = 73)</th>
<th>LAMICTAL 300 mg (n = 71)</th>
<th>LAMICTAL 500 mg (n = 72)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse Experience</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ataxia</td>
<td>10</td>
<td>10</td>
<td>25†</td>
</tr>
<tr>
<td>Blurred vision</td>
<td>10</td>
<td>11</td>
<td>25†</td>
</tr>
<tr>
<td>Diplopia</td>
<td>8</td>
<td>24†</td>
<td>49†</td>
</tr>
<tr>
<td>Dizziness</td>
<td>27</td>
<td>31</td>
<td>54†</td>
</tr>
<tr>
<td>Nausea</td>
<td>11</td>
<td>18</td>
<td>25†</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4</td>
<td>11</td>
<td>18†</td>
</tr>
</tbody>
</table>

*Significantly greater than placebo group (P<0.05)
†Significantly greater than group receiving LAMICTAL 300 mg (P<0.05).

Other events that occurred in more than 1% of patients but equally or more frequently in the placebo group included: asthma, back pain, chest pain, flatulence, menstrual disorder, myalgia, paresthesia, respiratory disorder, and urinary tract infection.

The overall adverse experience profile for LAMICTAL was similar between females and males, and was independent of age. Because the largest non-Caucasian racial subgroup was only 6% of patients exposed to LAMICTAL in placebo-controlled trials, there are insufficient data to support a statement regarding the distribution of adverse experience reports by race. Generally, females
LAMICTAL® (lamotrigine) Tablets

...receiving either adjunctive LAMICTAL or placebo were more likely to report adverse experiences than males. The only adverse experience for which the reports on LAMICTAL were greater than 10% more frequent in females than males (without a corresponding difference by gender on placebo) was dizziness (difference = 18.9%). There was little difference between females and males in the rates of discontinuation of LAMICTAL for individual adverse experiences.

Adverse Events in Pediatric Patients: Lennox-Gastaut Syndrome: In 169 patients with Lennox-Gastaut syndrome (26 patients were between the ages of 18 and 25), 38% of patients on LAMICTAL and 7.8% of patients on placebo discontinued due to adverse experiences. The most commonly reported adverse experiences that led to discontinuation were rash for patients treated with LAMICTAL and deterioration of seizure control for patients treated with placebo.

Incidence In a Controlled Adjunctive Trial in Adult and Pediatric Patients With Lennox-Gastaut Syndrome: The prescriber should be aware that the figures in Table 6 obtained when LAMICTAL was added to concurrent AED therapy cannot be used to predict the frequency of adverse experiences in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments, uses, or investigators. An inspection of these frequencies, however, does provide the prescriber with one basis to estimate the relative contribution of drug and nondrug factors to the adverse event incidences in the population studied.

Table 6: Treatment-Emergent Adverse Event Incidence in Placebo-Controlled Adjunctive Trial in Adult and Pediatric Patients With Lennox-Gastaut Syndrome (Events in at least 1% of patients treated with LAMICTAL and numerically more frequent than in the placebo group.)

<table>
<thead>
<tr>
<th>Body System</th>
<th>Percent of Patients Receiving LAMICTAL (%</th>
<th>Percent of Patients Receiving Placebo (%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body as a whole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Accidental injury</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>Flu syndrome</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Asthma</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Back pain</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Edema of the face</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Lab test abnormal</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Category</td>
<td>Occurrence</td>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Digestive</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Anorexia</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Stomatitis aphtha</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Tooth disorder</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Endocrine</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Cushing's syndrome</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Hemic and lymphatic</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Lymphadenopathy (enlarged cervical nodes)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Nervous system</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Ataxia</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Convulsions</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Tremor</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Agitation</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Coordination abnormal</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Emotional lability</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Nervousness</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Vertigo</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Bronchitis</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Skin</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Eczema</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Nail disorder</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Special senses</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Blepharitis</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>
Other Adverse Events Observed During All Clinical Trials For Adult and Pediatric Patients:

LAMICTAL has been administered to 3923 individuals for whom complete adverse event data was captured during all clinical trials, only some of which were placebo controlled. During these trials, all adverse events were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse events, similar types of events were grouped into a smaller number of standardized categories using modified COSTART dictionary terminology. The frequencies presented represent the proportion of the 3923 individuals exposed to LAMICTAL who experienced an event of the type cited on at least one occasion while receiving LAMICTAL. All reported events are included except those already listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug.

Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare adverse events are those occurring in fewer than 1/1000 patients.

Body as a Whole: Infrequent: Accidental injury, allergic reaction, chills, hallucination, infection, and malaise. Rare: Abdominal enlargement, abscess, photosensitivity, and suicide attempt.

Cardiovascular System: Infrequent: Flushing, migraine, palpitations, postural hypotension, syncope, tachycardia, and vasodilatation. Rare: Angina pectoris, atrial fibrillation, deep vein thrombophlebitis, hypertension, and myocardial infarction.

Dermatological: Infrequent: Acne, alopecia, dry skin, erythema, lipoatrophy, maculopapular rash, skin discolouration, sweating, Stevens-Johnson syndrome, vesiculobullous rash, and urticaria. Rare: Angioedema, erythema multiforme, fungal dermatitis, herpes zoster, leukoderma, pityriasis, pustular rash, and seborrhea.

Digestive System: Infrequent: Dysphagia, gingivitis, glossitis, gum hypertrophy, increased appetite, increased salivation, liver function tests abnormal, mouth ulceration, stomatitis, and thirst. Rare: Erosion, gastritis, gastrointestinal hemorrhage, gum hemorrhage, hematemesis, hemorrhagic coats, hepatitis, melena, stomach ulcer, and tongue edema.

Endocrine System: Rare: Goiter.

Hematologic and Lymphatic System: Infrequent: Anemia; ecchymosis, leukocytosis, leukopenia, and petechia. Rare: Eosinophilia, fibrin decrease, fibrinogen decrease, iron deficiency...
anemia, lymphocytosis, macrocytic anemia, and thrombocytopenia.

Metabolic and Nutritional Disorders: Infrequent: Peripheral edema, weight gain, and weight loss. Rare: Alcohol intolerance, alkaline phosphatase increase, bilirubinemia, general edema, and hyponatremia.

Musculoskeletal System: Infrequent: Joint disorder and twitching. Rare: Arthritis, bursitis, leg cramps, tendinous contracture, and pathological fracture.

Nervous System: Frequent: Amnesia, confusion, hostility, memory decrease, nyctagmus, and thinking abnormality. Infrequent: Abnormal dreams, abnormal gait, agitation, akathisia, apathy, aphasia, CNS depression, depersonalization, dyskinesia, dysphoria, euphoria, faintness, grand mal convulsions, hallucinations, hyperkinesia, hypertonia, hypoesthesia, libido increased, mind racing, myoclonus, panic attack, paranoid reaction, personality disorder, psychosis, sleep disorder, and stupor. Rare: Cerebrovascular accident, cerebellar syndrome, cerebral sinus thrombosis, choreoathetosis, CNS stimulation, delirium, delusions, dystonia, hemolysis, hyperagia, hypesthesia, hypoesthesia, hypokinesia, hypotonia, libido decreased, manic depression reaction, movement disorder, neurasthenia, neuropathy, paroxysm, and suicidal ideation.

Respiratory System: Infrequent: Epistaxis and hyperventilation. Rare: Bronchospasm, hiccup, and sinusitis.

Special Senses: Infrequent: Abnormality of accommodation, ear pain, oscillopsia, photophobia, taste perversion, and tinnitus. Rare: Deafness, dry eyes, lacrimation disorder, parosmia, ptosis, strabismus, taste loss, and uveitis.

Urogenital System: Infrequent: Female lactation, hematuria, polyuria, urinary frequency, urinary incontinence, urinary retention, and vaginal manifestations. Rare: Abnormal ejaculation, acute kidney failure, breast atrophy, breast neoplasm, breast pain, creatinine increase, cystitis, dysuria, epididymitis, impotence, kidney failure, kidney pain, menorrhagia, and urine abnormality.

Postmarketing and Other Experience: In addition to the adverse experiences reported during clinical testing of LAMICTAL, the following adverse experiences have been reported in patients receiving marketed LAMICTAL in other countries and from worldwide noncontrolled investigational use. These adverse experiences have not been listed above, and data are insufficient to support an estimate of their incidence or to establish causation. The listing is alphabetized: Alopecia, anemia, anorexia, disseminated intravascular coagulation, esophagitis, neutropenic anemia, hypersensitivity reaction, multinodular goiter, neutropenia, pancreatitis, pancytopenia, and progressive immunosuppression.

DRUG ABUSE AND DEPENDENCE: The abuse and dependence potential of LAMICTAL have not been evaluated in human studies.

OVERDOSAGE:

Human Overdose Experience: Experience with single or daily doses >700 mg is limited. During the clinical development of LAMICTAL, the highest known overdoses were in two women who each
LAMICTAL® (lamotrigine) Tablets

INGESTED DOSES ≥4000 mg. The plasma concentration of lamotrigine in one woman was 52 mcg/mL 4 hours after the ingestion (a value more than 10 times greater than that seen in clinical trials). She became comatose and remained comatose for 9 to 12 hours; no electrocardiographic abnormalities were detected. The other patient had dizziness, headache, and somnolence. Both women recovered without sequelae.

Among patients ≤16 years of age, the two highest known single doses of LAMICTAL have been
3000 mg by a 14-year-old female and approximately 1000 mg by a 4-year-old male. The 14-year-old female was taking LAMICTAL after the dose, she lost consciousness and was admitted to the hospital for supportive therapy, where she recovered fully (time to recovery not reported). The 4-year-old male was drowsy and agitated when found, and progressed to coma. He was given supportive therapy, and his condition improved rapidly with full recovery in 3 days.

Management of Overdose: There are no specific antidotes for LAMICTAL. Following a suspected overdose, hospitalization of the patient is advised. General supportive care is indicated, including frequent monitoring of vital signs and close observation of the patient. If indicated, emesis should be induced or gastric lavage should be performed; usual precautions should be taken to protect the airway. It should be kept in mind that lamotrigine is rapidly absorbed (see CLINICAL PHARMACOLOGY). It is uncertain whether hemodialysis is an effective means of removing lamotrigine from the blood. In six renal failure patients, about 20% of the amount of lamotrigine in the body was removed by hemodialysis during a 4-hour session. A Poison Control Center should be contacted for information on the management of overdose of LAMICTAL.

DOSAGE AND ADMINISTRATION: LAMICTAL is indicated as adjunctive therapy in adults with partial seizures and as adjunctive therapy in the generalized seizures of Lennox-Gastaut syndrome in pediatric and adult patients. Safety and effectiveness in pediatric patients below the age of 16 years other than those with Lennox-Gastaut syndrome have not been established (see BOX WARNING).

General Dosing Considerations: The risk of rashes is increased when the recommended initial dose and/or the rate of dose escalation of LAMICTAL is exceeded. There are suggestions, yet to be proven, that the risk of severe, potentially life-threatening rash may be increased by 1) coadministration of LAMICTAL with valproic acid (VPA), 2) exceeding the recommended initial dose of LAMICTAL, or 3) exceeding the recommended dose escalation for LAMICTAL. However, cases have been reported in the absence of these factors (see BOX WARNING). Therefore, it is important that the dosing recommendations be followed closely.

This section provides specific dosing recommendations for patients 2 to 12 years of age and patients greater than 12 years of age. Within each of these age groups, specific dosing recommendations are provided depending upon whether or not the patient is receiving VPA (Tables 7 and 8 for patients 2 to 12 years of age, Tables 9 and 10 for patients greater than 12 years of age). In addition, the section provides a discussion of dosing for those patients receiving concomitant AEDs that have not been systematically evaluated in combination with LAMICTAL.
LAMICTAL® (lamotrigine) Tablets
LAMICTAL® (lamotrigine) Chewable Dispersible Tablets

For dosing guidelines for LAMICTAL below, enzyme-inducing antiepileptic drugs (EIAEDs) include phenytoin, carbamazepine, phenobarbital, and primidone.

Patients 2 to 12 Years of Age: Recommended dosing guidelines for LAMICTAL added to an antiepileptic drug (AED) regimen containing VPA are summarized in Table 7. Recommended dosing guidelines for LAMICTAL added to EIAEDs are summarized in Table 8. Note that the starting doses and dose escalations listed below are different than those used in clinical trials; however, the maintenance doses are the same as in clinical trials. Smaller starting doses and slower dose escalations than those used in clinical trials are recommended because of the suggestions that the risk of rash may be decreased by smaller starting doses and slower dose escalations. Therefore, maintenance doses will take longer to reach in clinical practice than in clinical trials. It may take several weeks to months to achieve an individualized maintenance dose. It is likely that patients aged 2 to 5 years will require a maintenance dose at the higher end of the maintenance dose range.

The smallest available strength of LAMICTAL Chewable Dispersible Tablets is 5 mg, and only whole tablets should be administered. If the calculated dose cannot be achieved using whole tablets, the dose should be rounded down to the nearest whole tablet.

Pediatric patients who weigh less than 17 kg (37 lb) should not receive LAMICTAL because therapy cannot be initiated using the dosing guidelines (see Table 7 and Table 8) and the currently available tablet strengths (see WARNINGS).

**Table 7: LAMICTAL Added to an AED Regimen Containing VPA in Patients 2 to 12 Years of Age**

| Weeks 1 and 2 | 0.15 mg/kg/day in one or two divided doses, rounded down to the nearest 5 mg if the initial calculated daily dose of LAMICTAL is 2.5 to 5 mg, then 5 mg of LAMICTAL should be taken on alternate days for the first 2 weeks |
| Weeks 3 and 4 | 0.3 mg/kg/day in one or two divided doses, rounded down to the nearest 5 mg |

Usual maintenance dose: 1 to 5 mg/kg/day (maximum 250 mg/day in one or two divided doses). To achieve the usual maintenance dose, subsequent doses should be increased every 1 to 2 weeks as follows: Calculate 0.3 mg/kg/day, round this amount down to the nearest 5 mg, and add this amount to the previously administered daily dose.

---

25
Table 8: LAMICTAL Added to EIAEDs (Without VPA) in Patients 2 to 12 Years of Age

| Weeks 1 and 2 | 0.6 mg/kg/day in two divided doses, rounded down to the nearest 5 mg |
| Weeks 3 and 4 | 1.2 mg/kg/day in two divided doses, rounded down to the nearest 5 mg |

Usual maintenance dose: 5 to 15 mg/kg/day (maximum 400 mg/day in two divided doses). To achieve the usual maintenance dose, subsequent doses should be increased every 1 to 2 weeks as follows. Calculate 1.2 mg/kg/day, round this amount down to the nearest 5 mg, and add this amount to the previously administered daily dose every 1 to 2 weeks.

Patients Over 12 Years of Age: Recommended dosing guidelines for LAMICTAL added to VPA are summarized in Table 9. Recommended dosing guidelines for LAMICTAL added to EIAEDs are summarized in Table 10.

Table 9: LAMICTAL Added to an AED Regimen Containing VPA in Patients Over 12 Years of Age

| Weeks 1 and 2 | 25 mg every other day |
| Weeks 3 and 4 | 25 mg every day |

Usual maintenance dose: 100 to 400 mg/day (1 or 2 divided doses). To achieve maintenance, doses may be increased by 25 to 50 mg/day every 1 to 2 weeks. The usual maintenance dose in patients adding LAMICTAL to VPA alone ranges from 100 to 200 mg/day.

Table 10: LAMICTAL Added to EIAEDs (Without VPA) in Patients Over 12 Years of Age

| Weeks 1 and 2 | 50 mg/day |
| Weeks 3 and 4 | 100 mg/day in two divided doses |

Usual maintenance dose: 300 to 500 mg/day (in two divided doses). To achieve maintenance, doses may be increased by 100 mg/day every 1 to 2 weeks.

Because of an increased risk of rash, the recommended initial dose and subsequent dose escalations of LAMICTAL should not be exceeded (see BOX WARNING).

The usual maintenance doses identified in the tables above are derived from dosing regimens employed in the placebo-controlled adjunctive studies in which the efficacy of LAMICTAL was established. The advantage of using doses above those recommended in the tables above has not been established in controlled trials.

LAMICTAL Added to AEDs Other Than EIAEDs and VPA: The effect of AEDs other than EIAEDs and VPA on the metabolism of LAMICTAL cannot be predicted. Therefore, no specific dosing guidelines can be provided in that situation. Conservative starting doses and dose escalations (as
LAMICTAL® (lamotrigine) Tablets
with concomitant VPA would be prudent; maintenance dosing would be expected to fall between the maintenance dose with VPA and the maintenance dose without VPA, but with an EIAED.

Patients With Renal Functional Impairment: Initial doses of LAMICTAL should be based on patients' AED regimen (see above). Reduced maintenance doses may be effective for patients with significant renal functional impairment (see CLINICAL PHARMACOLOGY). Few patients with severe renal impairment have been evaluated during chronic treatment with LAMICTAL. Because there is inadequate experience in this population, LAMICTAL should be used with caution in these patients.

Discontinuation Strategy: For patients receiving LAMICTAL in combination with other AEDs, a reevaluation of all AEDs in the regimen should be considered if a change in seizure control or an appearance or worsening of adverse experiences is observed.

If a decision is made to discontinue therapy with LAMICTAL, a step-wise reduction of dose over at least 2 weeks (approximately 50% per week) is recommended unless safety concerns require a more rapid withdrawal (see PRECAUTIONS).

Discontinuing an EIAED should prolong the half-life of lamotrigine. Discontinuing VPA should shorten the half-life of lamotrigine.

Target Plasma Levels: A therapeutic plasma concentration range has not been established for lamotrigine. Dosing of LAMICTAL should be based on therapeutic response.

Administration of LAMICTAL Chewable Dispersable Tablets: LAMICTAL Chewable Dispersable Tablets may be swallowed whole, chewed, or dispersed in water or diluted fruit juice. If the tablets are chewed, consume a small amount of water or diluted fruit juice to aid in swallowing.

To disperse LAMICTAL Chewable Dispersable Tablets, add the tablets to a small amount of liquid (1 teaspoon or enough to cover the medication). Approximately 1 minute later, when the tablets are completely dispersed, swill the solution and consume the entire quantity immediately. No attempt should be made to administer partial quantities of the dispersed tablets.

HOW SUPPLIED: LAMICTAL Tablets, 25 mg, white, scored, shield-shaped tablets engraved with "LAMICTAL" and "25", bottles of 25 (NDC 0173-0633-25) and 100 (NDC 0173-0633-02).

Store at 15° to 30°C (59° to 86°F) in a dry place.

LAMICTAL Tablets, 100 mg, peach, scored, shield-shaped tablets engraved with "LAMICTAL" and "100", bottle of 100 (NDC 0173-0642-55).

LAMICTAL Tablets, 150 mg, cream, scored, shield-shaped tablets engraved with "LAMICTAL" and "150", bottle of 80 (NDC 0173-0643-60).

LAMICTAL Tablets, 200 mg, blue, scored, shield-shaped tablets engraved with "LAMICTAL" and "200", bottle of 60 (NDC 0173-0644-60).

Store at 15° to 30°C (59° to 86°F) in a dry place and protect from light.

LAMICTAL Chewable Dispersable Tablets, 5 mg, white, capsule-shaped tablets engraved with "GX CLS", bottle of 100 (NDC 0173-0526-00).

LAMICTAL Chewable Dispersable Tablets, 25 mg, white, super elliptical-shaped tablets engraved with "GX CL5", bottle of 100 (NDC 0173-0527-00).
LAMICTAL® (lamotrigine) Tablets

Information for the Patient

LAMICTAL® (lamotrigine) Tablets

200 mg, blue
150 mg, cream
100 mg, peach
20 mg, white

LAMICTAL® (lamotrigine) Chewable Dispersible Tablets

5 mg, white
20 mg, white
100 mg, white

Please read this leaflet carefully before you take LAMICTAL and read the leaflet provided with any refills, in case any information has changed. This leaflet provides a summary of the information about your medicine. Please do not throw away this leaflet until you have finished your medicine. This leaflet does not contain all the information about LAMICTAL and is not meant to take the place of talking with your doctor. If you have any questions about LAMICTAL, ask your doctor or pharmacist.

Information About Your Medicine:

1. The Purpose of Your Medicine:

Lamotrigine is intended to be used in combination with other medicines to treat seizures in people age 16 years or older and/or only those patients below the age of 16 years who have seizures associated with the Lennox-Gastaut syndrome. When taking lamotrigine, it is important to follow your doctor’s instructions.

2. Who Should Not Take LAMICTAL:

You should not take LAMICTAL if you had an allergic reaction to it in the past.

3. Side Effects to Watch For:

- Most people who take LAMICTAL tolerate it well. The most common side effects with LAMICTAL are dizziness, headache, blurred or double vision, lack of coordination, sleepiness, nausea, vomiting and rash.
- Although most patients who develop rash while receiving LAMICTAL have mild to moderate
LAMICTAL® (lamotrigine) Tablets

LAMICTAL® (lamotrigine) Chewable Dispersible Tablets symptoms, some individuals may develop a serious skin reaction that requires hospitalization. Rarely, deaths have been reported. These serious skin reactions are most likely to happen within the first 8 weeks of treatment with LAMICTAL. Serious skin reactions occur more often in children than in adults.

- Rashes may be more likely to occur if you: 1) take LAMICTAL in combination with valproic acid (DEPAKEN® or DEPAKOTE®), 2) take a higher starting dose of LAMICTAL than your doctor prescribed, or 3) increase your dose of LAMICTAL faster than prescribed.

- It is not possible to predict whether a mild rash will develop into a more serious reaction. Therefore, if you experience a skin rash, hives, fever, swollen lymph glands, painful sores in the mouth or around the eyes, or swelling of lips or tongue, tell a doctor immediately, since these symptoms may be the first signs of a serious reaction. A doctor should evaluate your condition and decide if you should continue taking LAMICTAL.

4. The Use of LAMICTAL During Pregnancy and Breast-feeding:

The effects of LAMICTAL during pregnancy are not known at this time. If you are pregnant or are planning to become pregnant, talk to your doctor. Some LAMICTAL passes into breast milk and the effects of this on infants are unknown. Therefore, if you are breast-feeding, you should discuss this with your doctor to determine if you should continue to take LAMICTAL.

5. How to Use LAMICTAL:

- It is important to take LAMICTAL exactly as instructed by your doctor. LAMICTAL must be added slowly to your current treatment. It may take several weeks or months before your final dosage can be determined by your doctor, based on your response.
- Do not increase your dose of LAMICTAL or take more frequent doses than those indicated by your doctor.
- If you miss a dose of LAMICTAL, do not double your next dose.
- Do NOT stop taking LAMICTAL or any of your other seizure medicines unless instructed by your doctor.
- Use caution before driving a car or operating complex, hazardous machinery until you know if LAMICTAL affects your ability to perform these tasks.
- Tell your doctor if your seizures get worse or if you have any new types of seizures.
- Always tell your doctor and pharmacist if you are taking or plan to take any other prescription or over-the-counter medicines.

6. How to Take LAMICTAL:

LAMICTAL Tablets should be swallowed whole. Chewing the tablets may leave a bitter taste. LAMICTAL Chewable Dispersible Tablets may be swallowed whole, chewed, or mixed in water or diluted fruit juice. If the tablets are chewed, consume a small amount of water or diluted fruit juice to aid in swallowing.

To disperse LAMICTAL Chewable Dispersible Tablets, add the tablets to a small amount of liquid (1 teaspoon, or enough to cover the medication) in a glass or spoon. Approximately 1 minute later, when the tablets are completely dispersed, mix the solution and take the entire amount immediately.
7. Storing Your Medicine:
Store LAMICTAL at room temperature away from heat and light. Always keep your medicines out of the reach of children.
This medicine was prescribed for your use only to treat seizures. Do not give the drug to others.
If your doctor decides to stop your treatment, do not keep any leftover medicine unless your doctor tells you to. Throw away your medicine as instructed.

GlaxoWellcome
Glaxo Wellcome Inc.
Research Triangle Park, NC 27709

DEPAKENE and DEPAKOTE are registered trademarks of Abbott Laboratories.

US Patent No. 4,802,017

©Copyright 1998 Glaxo Wellcome Inc. All rights reserved.

August 1998

PHARMACIST—DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT

Information for the Patient

LAMICTAL (lamotrigine) Tablets

| 25 mg, white | 100 mg, peach | 150 mg, cream | 200 mg, blue |

LAMICTAL (lamotrigine) Chewable Dispersible Tablets

| 5 mg, white | 25 mg, white | 100 mg, white |

Please read this leaflet carefully before you take LAMICTAL and read the leaflet provided with any refill in case any information has changed. This leaflet provides a summary of the information about your medicine. Please do not throw away this leaflet until you have finished your medicine. This
LAMICTAL® (lamotrigine) Tablets

1. The Purpose of Your Medicine:

Lamotrigine is intended to be used in combination with other medicines to treat seizures in people age 16 years or older and/or only those patients below the age of 16 years who have seizures associated with the Lennox-Gastaut syndrome. When taking lamotrigine, it is important to follow your doctor’s instructions.

2. Who Should Not Take LAMICTAL:

You should not take LAMICTAL if you had an allergic reaction to it in the past.

3. Side Effects to Watch For:

- Most people who take LAMICTAL tolerate it well. The most common side effects with LAMICTAL are dizziness, headache, blurred or double vision, lack of coordination, sleepiness, nausea, vomiting, and rash.
- Although most patients who develop rash while receiving LAMICTAL have mild to moderate symptoms, some individuals may develop a serious skin reaction. Rarely, deaths have been reported. These serious skin reactions are most likely to happen within the first 8 weeks of treatment with LAMICTAL. Serious skin reactions occur more often in children than in adults. Rashes may be more likely to occur if you: 1) take LAMICTAL in combination with valproic acid (DEPaken® or DEPAKOTE®), 2) take a higher starting dose of LAMICTAL than your doctor prescribed, or 3) increase your dose of LAMICTAL faster than prescribed.
- It is not possible to predict whether a mild rash will develop into a more serious reaction. Therefore, if you experience a skin rash, hives, fever, swollen lymph glands, painful sores in the mouth or around the eyes, or swelling of lips or tongue, tell a doctor immediately.

4. The Use of LAMICTAL During Pregnancy and Breast-feeding:

The effects of LAMICTAL during pregnancy are not known at this time. If you are pregnant or are planning to become pregnant, talk to your doctor. Some LAMICTAL passes into breast milk and the effects of this on infants are unknown. Therefore, if you are breast-feeding, you should discuss this with your doctor to determine if you should continue taking LAMICTAL.

5. How to Use LAMICTAL:

- It is important to take LAMICTAL exactly as instructed by your doctor. LAMICTAL must be added slowly to your current treatment. It may take several weeks or months before your final dosage can be determined by your doctor, based on your response.
- Do not increase your dose of LAMICTAL or take more frequent doses than those indicated by your doctor.
LAMICTAL® (lamotrigine) Tablets

- If you miss a dose of lamotrigine, do not double your next dose.
- Do NOT stop taking LAMICTAL or any of your other seizure medicines unless instructed by your doctor.
- Use caution before driving a car or operating complex, hazardous machinery until you know if LAMICTAL affects your ability to perform these tasks.
- Tell your doctor if your seizures get worse or if you have any new types of seizures.
- Always tell your doctor and pharmacist if you are taking or plan to take any other prescription or over-the-counter medicines.

6. How to Take LAMICTAL:

LAMICTAL Tablets should be swallowed whole. Chewing the tablets may leave a bitter taste.

LAMICTAL Chewable Dispersible Tablets may be swallowed whole, chewed, or mixed in water or diluted fruit juice. If the tablets are chewed, consume a small amount of water or diluted fruit juice to aid in swallowing.

To disperse LAMICTAL Chewable Dispersible Tablets, add the tablets to a small amount of liquid (1 teaspoon, or enough to cover the medication) in a glass or spoon. Approximately 1 minute later, when the tablets are completely dispersed, mix the solution and take the entire amount immediately.

7. Storing Your Medicine:

Store LAMICTAL at room temperature away from heat and light. Always keep your medicines out of the reach of children.

This medicine was prescribed for your use only to treat seizures. Do not give the drug to others.

If your doctor decides to stop your treatment, do not keep any leftover medicine unless your doctor tells you to. Throw away your medicine as instructed.

GlaxoWellcome
Glaxo Wellcome Inc.
Research Triangle Park, NC 27709

DEPAKENE and DEPAKOTE are registered trademarks of Abbott Laboratories.

US Patent No. 4,602,017

©Copyright 1998 Glaxo Wellcome Inc. All rights reserved.

August 1998

RL-612

32